metabolic health

Is Inositol Cardiometabolic Randomized Trial safe?

Updated October 2026

Quick Answer

Inositol Cardiometabolic Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Background Inositol and its derivatives may help mitigate risks associated with cardiovascular diseases; however, existing evidence remains inconsistent.

Key Takeaways

  • 01Background Inositol and its derivatives may help mitigate risks associated with cardiovascular diseases; however, existing evidence remains inconsistent. [Delavar MA (2025)]
  • 02Heterogeneity was assessed via the Cochrane Chi-squared test and Galbraith plots, while the ROBI tool evaluated bias risk. [Delavar MA (2025)]
  • 03Significant reductions in BMI (WMD (95%CIs):-0.57 kg/m²(-1.10, -0.03), I²=88.6), waist-to-hip ratio(WMD (95%CI):-0.02(-0.04, -0.001), I²=84.1), and waist circumference (WMD (95%CI):-2.36 cm(-4.39, -0.33) I²=55.0) were noted with high heterogeneity and low to very low certainty evidence. [Delavar MA (2025)]
  • 04Objectives The primary aim of this systematic review and meta-analysis of RCTs was to quantify the effects of inositol and its stereoisomers on anthropometric, and cardiometabolic measures. [Delavar MA (2025)]
The current Migaku evidence database contains 1 reusable source document for Inositol Cardiometabolic Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - Background Inositol and its derivatives may help mitigate risks associated with cardiovascular diseases; however, existing evidence remains inconsistent. [Delavar MA (2025); evidence level 1] - Heterogeneity was assessed via the Cochrane Chi-squared test and Galbraith plots, while the ROBI tool evaluated bias risk. [Delavar MA (2025); evidence level 1] - Significant reductions in BMI (WMD (95%CIs):-0.57 kg/m²(-1.10, -0.03), I²=88.6), waist-to-hip ratio(WMD (95%CI):-0.02(-0.04, -0.001), I²=84.1), and waist circumference (WMD (95%CI):-2.36 cm(-4.39, -0.33) I²=55.0) were noted with high heterogeneity and low to very low certainty evidence. [Delavar MA (2025); evidence level 1] - Objectives The primary aim of this systematic review and meta-analysis of RCTs was to quantify the effects of inositol and its stereoisomers on anthropometric, and cardiometabolic measures. [Delavar MA (2025); evidence level 1] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Learn next

Keep learning from this answer

GuideSupplement Interactions: What You Need to Know Before StackingLegacy library material — check the original sources.GuideMagnesium Glycinate FAQ: dosage, timing, safety, and resultsLegacy library material — check the original sources.GuideIs Magnesium Glycinate safe? Side effects and interactionsLegacy library material — check the original sources.DataInositol Cardiometabolic Randomized Trial Evidence TableLegacy library material — check the original sources.DataSesame Oil Cardiometabolic Randomized Trial Evidence TableLegacy library material — check the original sources.DataOmega-7 Cardiometabolic Randomized Trial Evidence TableLegacy library material — check the original sources.

Sources

  1. Inositol supplementation efficacy in improving key cardiometabolic and anthropometric indices: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials.